Manifold Bio is an AI-driven protein engineering company developing tissue-targeted biologics with a focus on central nervous system (CNS) delivery for neurodegenerative diseases.
Company Overview
Manifold Bio's tagline is "Organism-scale intelligence, designed in vivo." The company's mission is creating tissue-targeted biologics while building the "virtual organism"—a predictive model of living systems that integrates high-throughput in vivo data.
Leadership Team
Gleb Kuznetsov, PhD – Co-Founder & CEO
Pierce Ogden, PhD – Co-Founder & CTO
Shane Lofgren – Co-Founder & Head of Portfolio Development and Strategy
Doug Williams, PhD – Chair of Strategic Advisory Board
Technology Platform: mDesign Engine
Manifold Bio has developed the mDesign Engine, which combines AI-guided protein design with in vivo testing capabilities. Key features include:
mCodes (multiplexed protein barcodes decoded via NGS) for high-throughput tracking of protein binders in living systems
Direct measurement of pharmacokinetics and biodistribution in vivo, rather than relying solely on in vitro assays
Integration of experimental validation at million-scale alongside AI-driven design
Partnership with NVIDIA
...
Overview
Manifold Bio is an AI-driven protein engineering company developing tissue-targeted biologics with a focus on central nervous system (CNS) delivery for neurodegenerative diseases.
Company Overview
Manifold Bio's tagline is "Organism-scale intelligence, designed in vivo." The company's mission is creating tissue-targeted biologics while building the "virtual organism"—a predictive model of living systems that integrates high-throughput in vivo data.
Leadership Team
Gleb Kuznetsov, PhD – Co-Founder & CEO
Pierce Ogden, PhD – Co-Founder & CTO
Shane Lofgren – Co-Founder & Head of Portfolio Development and Strategy
Doug Williams, PhD – Chair of Strategic Advisory Board
Technology Platform: mDesign Engine
Manifold Bio has developed the mDesign Engine, which combines AI-guided protein design with in vivo testing capabilities. Key features include:
mCodes (multiplexed protein barcodes decoded via NGS) for high-throughput tracking of protein binders in living systems
Direct measurement of pharmacokinetics and biodistribution in vivo, rather than relying solely on in vitro assays
Integration of experimental validation at million-scale alongside AI-driven design
Partnership with NVIDIA
Manifold Bio collaborates with NVIDIA for million-scale experimental validation of AI-driven protein binder design, leveraging GPU-accelerated computing for protein structure prediction and design.
Alzheimer's Disease (AD): Amyloid-beta antibodies with high CNS levels, engaging brain immune system to clear plaques
Tau-targeting approaches: Antibodies and oligonucleotides for Alzheimer's and rare diseases
Parkinson's Disease (PD): Alpha-synuclein antibodies and oligonucleotides
Peripheral-Targeted Programs
Undisclosed target for cardiometabolic disease (adipose tissue targeting with detargeting of liver/kidney)
Strategic Partnerships
Roche Collaboration
Manifold Bio has a strategic collaboration with Roche to develop multiple next-generation brain shuttles for neurological diseases. This partnership leverages Roche's development and commercialization expertise with Manifold Bio's mShuttle technology for blood-brain barrier crossing.
Neurodegeneration" style="color:#4fc3f7;margin:1.5rem 0 0.6rem;font-size:1.15rem;font-weight:700;border-bottom:2px solid rgba(79,195,247,0.3);padding-bottom:0.3rem">Relevance to Neurodegeneration
Manifold Bio's platform addresses several critical challenges in developing therapeutics for Alzheimer's disease and Parkinson's disease:
BBB Penetration: The mShuttle technology enables delivery of biologics across the blood-brain barrier, a major hurdle in CNS drug development
Protein Engineering: AI-driven design of antibody therapeutics with optimized binding affinity and pharmacokinetics
Oligonucleotide Delivery: Development of brain-targeted oligonucleotides for gene silencing approaches in neurodegenerative diseases
Tissue Specificity: Platform enables targeting specific tissues while detargeting others, reducing off-target effects
Comparison to Other AI Protein Engineering Companies
| Company | Focus | Differentiation | |---------|-------|-----------------| | Manifold Bio | In vivo validation, brain shuttles | Direct testing in living systems, BBB crossing | | Generate Biomedicines | Protein generation | Generates novel protein scaffolds | | Absci | Antibody design | AI + synthetic biology platform | | Evotec | Drug discovery services | Broad platform, multiple partnerships |